Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus PHENURONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus PHENURONE.
DEPAKOTE CP vs PHENURONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Category C
Category C
Anticonvulsant
Anticonvulsant